Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132549 | 0.82 | APAF1 (0.57) | ALDH1A1APAF1HDAC1HDAC6POLB | |
| SCHEMBL7146651 | 0.76 | APAF1 (0.80) | KDM4EALDH1A1HPGDAPAF1HDAC1 | |
| SCHEMBL7134087 | 0.73 | HTR5A (0.53) | HDAC6PRMT5WDR77 | |
| SCHEMBL13942726 | 0.72 | CDK4 (0.93) | CDK4CCND1 | |
| SCHEMBL13942742 | 0.69 | CDK4 (1.00) | CDK4CCND1 | |
| SCHEMBL3079170 | 0.69 | MAPT (0.71) | CDK4CCND1KDM4EALDH1A1MAPT | |
| SCHEMBL7245981 | 0.68 | DRD3 (0.68) | CDK4CCND1KDM4EAPAF1POLB | |
| SCHEMBL273794 | 0.68 | CDK4 (0.56) | CDK4CCND1ALDH1A1POLB | |
| SCHEMBL12868422 | 0.68 | CDK4 (0.77) | CDK4CCND1MAPT | |
| SCHEMBL276061 | 0.67 | ABCG2 (0.60) | CDK4CCND1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015451-B1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA NV (BE) | 2003-06-18 | — | — | EP | disclosed |
| US-6506768-B2 | Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-14 | — | — | US | disclosed |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2002-08-01 | — | — | US | disclosed |
| US-6303614-B1 | FOR THERAPY PSYCHOTIC DISORDER SELECTED FROM DEPRESSION, ANXIETY OR PSYCHOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103209-A1 | Tetrahydro gamma-carbolines | OPRD1, CYP1B1, CBR1 | CDK4 1312/4885CCND1 303/4885KDM4E 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.